Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Investment analysts at Oppenheimer initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock. A number of other analysts have also commented on the company. D. Boral Capital restated a […]

Leave a Reply

Your email address will not be published.

Previous post Leerink Partners Begins Coverage on Medpace (NASDAQ:MEDP)
Next post Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns “Buy” Rating from HC Wainwright